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Abstract
Background: Prebiotic galacto-oligosaccharides (GOS) have an extensively demonstrated beneficial impact on intestinal
health. In this study, we determined the impact of GOS diets on hallmarks of gut aging: microbiome dysbiosis,
inflammation, and intestinal barrier defects (“leaky gut”). We also evaluated if short-term GOS feeding influenced how the
aging gut responded to antibiotic challenges in a mouse model of Clostridioides difficile infection. Finally, we assessed if
colonic organoids could reproduce the GOS responder—non-responder phenotypes observed in vivo.
Results: Old animals had a distinct microbiome characterized by increased ratios of non-saccharolytic versus saccharolytic
bacteria and, correspondingly, a lower abundance of β-galactosidases compared to young animals. GOS reduced the
overall diversity, increased the abundance of specific saccharolytic bacteria (species of Bacteroides and Lactobacillus),
increased the abundance of β-galactosidases in young and old animals, and increased the non-saccharolytic organisms;
however, a robust, homogeneous bifidogenic effect was not observed. GOS reduced age-associated increased intestinal
permeability and increased MUC2 expression and mucus thickness in old mice. Clyndamicin reduced the abundance
Bifidobacterium while increasing Akkermansia, Clostridium, Coprococcus, Bacillus, Bacteroides, and Ruminococcus in old mice.
The antibiotics were more impactful than GOS on modulating serum markers of inflammation. Higher serum levels of IL-
17 and IL-6 were observed in control and GOS diets in the antibiotic groups, and within those groups, levels of IL-6 were
higher in the GOS groups, regardless of age, and higher in the old compared to young animals in the control diet
groups. RTqPCR revealed significantly increased gene expression of TNFα in distal colon tissue of old mice, which was
decreased by the GOS diet. Colon transcriptomics analysis of mice fed GOS showed increased expression of genes
involved in small-molecule metabolic processes and specifically the respirasome in old animals, which could indicate an
increased oxidative metabolism and energetic efficiency. In young mice, GOS induced the expression of binding-related
genes. The galectin gene Lgals1, a β-galactosyl-binding lectin that bridges molecules by their sugar moieties and is an
important modulator of the immune response, and the PI3K-Akt and ECM-receptor interaction pathways were also
induced in young mice. Stools from mice exhibiting variable bifidogenic response to GOS injected into colon organoids
in the presence of prebiotics reproduced the response and non-response phenotypes observed in vivo suggesting that
the composition and functionality of the microbiota are the main contributors to the phenotype.
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Conclusions: Dietary GOS modulated homeostasis of the aging gut by promoting changes in microbiome composition
and host gene expression, which was translated into decreased intestinal permeability and increased mucus production.
Age was a determining factor on how prebiotics impacted the microbiome and expression of intestinal epithelial cells,
especially apparent from the induction of galectin-1 in young but not old mice.
Keywords: Gut microbiome, Prebiotics, Bifidobacterium, Intestinal permeability, Host-microbiota interactions, Diet,
Antibiotics, Metagenomics, Transcriptomics, Organoids
Background
The fragility of the gut microbiota and consequent
susceptibility to disease are accentuated at the beginning
and at the end of life. The aging gut microbiome has a
demonstrated altered bacterial diversity with reductions
in the abundance of beneficial microorganisms [1–12].
Imbalances in the gut microbiota promote a basal
inflammatory state and enhance susceptibility to viral
and bacterial infections, including Clostridioides difficile
[13–15]. The elderly human gut microbiome has been
reported to have a reduced abundance of Bifidobacter-
ium, Faecalibacterium prausnitzii, and Clostridium XIVa
[2–4] and increased Clostridium perfringens, coliforms,
enterococci [1], Streptococcus, Staphylococcus, and Entero-
bacteria [2, 3, 5–7]. Accordingly, the aging human gut
microbiota shows a loss of genes involved in the production
of short-chain fatty acids (SCFAs) and a decrease in
saccharolytic potential, with a reduced representation of
starch, sucrose, galactose, glycolysis, and gluconeogenesis
metabolism pathways; a concomitant loss of fibrolytic mi-
croorganisms; and an overall increase in proteolytic func-
tion [16]. Consistent with human microbiome observations,
old mice have a distinctive gut microbiome characterized
by lower phylogenetic diversity, increased representation of
potentially pathogenic taxa including Rikenella and Entero-
bacteriaceae, and reduced representation of di-, oligo-, and
polysaccharide utilization genes [17].
The ability of bacteria to access host tissues is limited
by the mucus layer in healthy individuals. In mice, the
colon of old animals has a thinner firm mucus layer (<
10 μm) compared to young mice (20–25 μm), resulting
in a failure to spatially compartmentalize the microbiota
to the intestinal lumen [18, 19]. However, the number of
mucus-producing goblet cells does not decline in the
specialized follicle-associated epithelium in aged mice
[20]. The mucus protein composition is relatively homo-
geneous along the intestine; however, the main mucin
component synthesized and secreted by intestinal goblet
cells, MUC2, shows region-specific O-glycan patterns
[21, 22]. Changes in properties of the mucus barrier have
been associated with shifts in bacterial community com-
position [23]. Conversely, beneficial microorganisms like
Lactobacillus plantarum [24] and Akkermansia mucini-
phila [25] have been shown to promote an increase in
mucus thickness and improve host tight junctions in aging
animals, reducing permeability. Likewise, Bifidobacterium
longum and B. longum subsp. infantis provided protection
against deterioration of the colonic mucus layer, counter-
acting negative influences of Western diets on mucus
hyper-degradation by enhancing production [26, 27].
An increased inflammatory state is another hallmark
of gut aging [28]. Aging changes the balance between
inflammatory and anti-inflammatory cytokines favoring
an excessive production of IL-6, TNFα, and IL-1β, directly
affecting intestinal permeability [28, 29]. Traditionally,
immuno-senescence, which is a decrease in the efficiency
of the immune system over time, has been considered the
largest contributor to increases in inflammatory mediators
[30, 31]. However, recent studies have highlighted a
prominent role of dysbiotic states of the gut micro-
biota in inflammatory bowel conditions and metabolic
diseases [32, 33], which show age-related increases in
incidence [34].
Prebiotic β(1-4) galacto-oligosaccharides (GOS) are
complex carbohydrates that are resistant to digestion in
the upper gastrointestinal tract. GOS arrive at the colon
intact and consequently increase the abundance of
specific primary and secondary degraders, resulting in an
expanded probiome (beneficial members of the intestinal
microbiota) [35]. GOS and fructo-oligosaccharides are
the preferred prebiotics currently added to commercial
infant formula to mimic the beneficial effects of the
human milk oligosaccharides (HMOs) in breast milk
[36]. Akkerman et al. [37] recently reviewed the effects
of non-digestible carbohydrates in infant formulas as
substituents of HMOs on the gut microbiota and matur-
ation and stated that, beyond a well-established role in
bifidogenesis, GOS also act as soluble decoy receptors to
prevent adhesion of pathogens to epithelial cells, stimu-
late tight junctions, enhance intestinal barrier function
through modulation of goblet cells [38], and reduce the
release of the inflammatory marker CXCL8 by Caco-2
cells [39]. In addition, GOS support intestinal development
in piglets, increasing the expression levels of β-defensins-2
and sIgA, suggesting improvement of mucosal immune
responses [40]. In adults, increases in the abundance of Bifi-
dobacterium upon GOS consumption have been reported
in humans and animal models [41–45]. We demonstrated
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that specific bifidobacteria (B. longum, B. adolescentis, B.
catenulatum, and B. breve) increased when lactose-
intolerant adults received purified GOS [46, 47]. We also
demonstrated that pure GOS are capable of increasing the
abundance of beneficial bacteria including Faecalibacter-
ium prausnitzii and species of Lactobacillus, Christensenel-
laceae, Collinsella, Prevotella, and Catenibacterium [45,
47]. In addition, GOS directly induce the expression of
MUC2, TFF3, and RETNLB in the colonic adenocarcinoma
LS174T cell line, which exhibits a goblet cell-like phenotype
[38]. Finally, studies in humans showed that GOS signifi-
cantly increased the numbers of bifidobacteria, phagocyt-
osis, NK cell activity, and anti-inflammatory IL-10 in
healthy elderly individuals, with a significant reduction in
the production of pro-inflammatory cytokines (IL-6, IL-1β,
and tumor necrosis factor-α) [48].
Based on the demonstrated effects of GOS on infants
and adults, our study aimed to determine the impact of
pure GOS [49] on the hallmarks of gut aging. We also
evaluated the effect of short-term GOS feeding on how
the aging gut microbiome responds to antibiotic chal-
lenges, since these interventions are common and rele-
vant in older adults. In fact, in the years 2007 to 2009,
patients aged ≥ 65 years used more antimicrobials, at
1.10 per person per year, compared to 0.88 antimicro-
bials used per person per year in patients aged 0–64
years [50]. Antibiotics induce gut microbiome distur-
bances, persistent through the constant presence in the
food supply [51] or by introducing new and potentially
stable changes with each cycle of antibiotic administra-
tion [52, 53]. Amidst these microbiota disturbances, the
prevalence of infection by opportunistic pathogens,
including Clostridioides difficile, is dramatically overrep-
resented in elderly populations [13]; thus, we evaluated
if short-term GOS feeding influenced how the aging gut
responded to the antibiotic challenges of a model of
Clostridioides difficile infection to lay down the ground-
work for future studies focused on prebiotics as prevent-
ive treatments against infection. Finally, we evaluated if
colonic organoids [54] reproduced the in vivo response
to GOS. Our findings add further evidence to previous
limited studies on age-associated dysbiosis and intestinal
physiology, providing valuable insights into how dietary
GOS impact the microbiome composition and function-
ality, intestinal barrier function, and biomarkers of in-
flammation in an animal model of aging.
Results
Impact of GOS and antibiotics on the gut microbiome
A cohort of twenty-four young (6 weeks) and old (60
weeks) female C57BL/6J SPF mice (N = 48) were fed the
control diet for 20 days (microbiome normalization period)
and then switched to the experimental diet containing pre-
biotics for an additional 2 weeks (Fig. 1a). Analysis of 16S
rRNA amplicon sequencing data performed on longitudinal
time points 1 (T1, day 20, after normalization period), 2
(T2, day 35), 3 (T3, day 38), 4 (T4, day 42), and 5 (T5, day
50) assigned 190 distinct bacterial taxa, when the analysis
was performed at the equivalent of species-level in QIIM
E2.
Analysis of alpha diversity revealed a decrease in
phylogenetic diversity in old and young animals receiv-
ing the prebiotics diet at T2, day 35 (repeated measures
ANOVA with pairwise comparisons P < 0.05) (Fig. 1b).
Introduction of antibiotics at T3 reduced diversity in
control-fed young and had a variable effect in old ani-
mals but had little impact on GOS-fed old mice. These
antibiotic-driven changes in alpha diversity persisted
through T4 and T5, revealing higher diversity in
antibiotic-free, control-fed animals in both young and
old animals. Animals did not lose weight during the
antibiotic treatments. Likewise, none of the animals ex-
hibited any signs of gastrointestinal distress or reduced
activity before the clindamycin IP injection. After admin-
istration of clindamycin, mice exhibited temporary
runny stools (T4).
Analysis of saccharolytic and non-saccharolytic
bacteria (Fig. 1c) showed that GOS increased the relative
abundance of mostly non-saccharolytic bacteria, driven
by Akkermansia, (Figure S1), reducing the abundance of
bacteria of undetermined metabolism at T2. These
changes persisted through T5 in animals that were not
treated with antibiotics, but additional shifts were
observed in antibiotic-treated animals, increasing the
abundance of saccharolytic taxa at T3–T4 with reduc-
tions in both non-saccharolytic and undetermined taxa.
Although the bifidogenic effect of GOS has been previ-
ously reported by us and others [41, 45, 47, 55], we did
not observe a consistently significant increase in the
abundance of bifidobacteria in old or young animals
fed GOS diet, also in accordance with previous
reports of the responder-non-responder phenotype
(Fig. 6a, left).
Principal coordinate analysis (PCoA) plots showed sig-
nificant differences in microbiome composition between
old and young mice prior to GOS treatment (ANOSIM
R = 0.45, P = 0.001, PERMANOVA pseudo-F = 3.8, P =
0.001) at day 20 (T1) (Fig. 2a). We observed clustering
of GOS-fed old and young mice (OG2 and YG2) away
from control-fed animals and sub-clusters at T1 that
separated control old and young animals. The separation
between GOS and control clusters persisted in T2–T3,
and sub-clustering was determined by the first antibiotic
treatment. A more extreme effect of the antibiotics was
observed in mice fed the control diet at T4 (Fig. 2c). At
this time, the separation by diet persisted, but the clus-
tering by age in the non-antibiotic control young and
old mice was not observed. Finally, we observed
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Fig. 1 Prebiotic GOS and antibiotics decrease microbiome diversity in the gut. (a). Experimental design outlining time points T1 (post-standardization),
T2 (post-specialized diet), T3 (post-antibiotics in water), T4 (post-clindamycin IP injection), and T5 (pre-sacrifice) (N = 48) (b). Impact of the different
treatments on phylogenetic diversity. GOS reduced diversity in both old and young animals. Alpha diversity declined with GOS consumption (T2) and
antibiotic administration (T3, in young mice) and remained consistent through T5. c Relative abundance of saccharolytic, non-saccharolytic, and
bacteria of undetermined metabolism over time. Line colors are as in Fig. 1b
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clustering by diet and antibiotics at T5, with samples
from both antibiotic treatments grouping together in
the GOS animals but not control. These results indi-
cate a clear influence of diet on the response of the
microbial community to antibiotics. Analysis at the
genus level identified 48 taxa significantly changed
from T4 to T5 upon clindamycin injection in at least
one of the groups in our analysis (Old_control, Old_GOS,
Young_control, Young_GOS) (Supplementary Text).
Interestingly, while the antibiotic decreased the abundance
of Bifidobacterium and Lactobacillus in young and old
mice in both diets, clindamycin increased the relative
abundance of non-saccharolytic bacteria in animals
(young and old) receiving the control diet.
To investigate whether compositional differences were









Fig. 2 Unweighted UniFrac PCoA plots and differences in the relative abundance of specific bacteria at different time points and treatments (a). The
T1–T2 PCoA plot (left) revealed the baseline differences between old and young mice (OC, old mice, control diet; OG, old mice, GOS diet; YC, young
mice, control diet; YG, young mice, GOS diet). The middle panel shows the prebiotic impact on young (light purple) and old (pink) mice compared to
the control diet (purple = young control, red = old control). The right panel shows the composed differences in relative abundances by age, diet, and
time point. b The T2–T3 PCoA plot (left) and genus-level analysis (middle) showed the impact of the antibiotic treatment in water on both diet
groups. Middle panel: control and GOS diets as before. Light blue dots represent no antibiotic treatment, and dark blue dots represent antibiotic
treatment. c The T3–T4 PCoA plot (left) and genus-level analysis (middle) represent the samples immediately after clindamycin IP injection. The graphs
did not show dramatic impacts to the microbiome, which were clearly visible in d the T4–T5 PCoA and taxa plots
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conducted whole-genome shotgun (WGS) sequencing of
stool collected from 6 old and 6 young animals (not
treated with antibiotics) at time point 1 (control diet)
and at time point 5 (GOS diet). First degraders encoding
β-galactosidases and β-glucosidases metabolize GOS in
the colon generating lactate and acetate [56]. In the
healthy adult gut, secondary degraders including Faecalibac-
terium [57] and Roseburia [58] utilize these primary fermen-
tation products to generate butyrate, which directly benefits
host physiology [59–61]. The gene family output of
HUMAnN2 identified 29 entries as β-galactosidases, the
essential enzymes for the initial catabolism of GOS by
primary degraders. Those included β-galactosidases
(EC:3.2.1.23), phospho-β-galactosidases (EC:3.2.1.85),
and arabinogalactan endo-1,4- β-galactosidases (EC:
3.2.1.89). β-galactosidases catalyze the hydrolysis of
terminal, non-reducing beta-D-galactoside residues,
while phospho-β galactosidases hydrolyze 6-phospho- β-
D-galactoside residues. Arabinogalactan endo-1,4- β-
galactosidases hydrolyze (1➔4)-β-D-galactosidic linkages
in type I arabinogalactans. Clustering of relative abun-
dance of β-galactosidases showed that most samples in
the old control group had significantly (Kruskal-Wallis
FDR corrected P < 0.05) reduced abundance of unclassi-
fied β-galactosidases as well as β-galactosidases from Bac-
teroides thetaiotaomicron and Akkermansia muciniphila,
abundance of which was increased in the old GOS group
(Fig. 3a). Interestingly, most samples from control young
and control old clustered within their own group, while
GOS-fed mice (young and old) clustered mostly in one
group. Figure 3b shows the box plots of representatives

















































































Fig. 3 a Whole-genome shotgun (WGS) sequencing of stool samples showed that GOS treatment significantly modified the abundance of 22 out
of 29 of beta-galactosidases in old and young mice (*Kruskal-Wallis FDR-corrected P < 0.05). b Representative patterns of abundance of beta-
galactosidases from B. pseudolongum, L. johnsonii, and E. faecalis
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both young and old animals), Lactobacillus johnsonii (only
increased by GOS in young animals), and Enterococcus
faecalis (overrepresented in the old control group) that
had low read counts, and hence, their pattern of represen-
tation could not be clearly assessed from the heatmap.
GOS impact on intestinal permeability, biomarkers of
inflammation, and mucin production
Assessment of gut barrier function showed significantly
increased intestinal permeability in old compared to
young mice, with decreased values in old animals fed
GOS (Fig. 4a(i)). No significant differences were ob-
served between control and GOS diets in young animals.
GOS diet increased the mucus abundance and thickness
in the lumen of old mice (2 × 2 ANOVA P < 005) (Fig.
4a(iii)), but a less pronounced effect was observed in young
animals. Imaging analysis of PAS-stained colon tissues using
the ImageJ software confirmed the increased abundance of
mucin/mucin-producing cells (blue/purple) in the old GOS
group compared to all of the other groups (Figure S2).
Epithelial surface integrity is maintained in part by
genes in the trefoil factor (TFF) family including TFF3
[62]. TFF3 binds to the cysteine-rich amino terminal
von Willebrand factor (vWF) of MUC2 enhancing the
protection of the gastrointestinal mucosa against injury
through interactions with mucins [63]. The resistin-like
molecule (RELM) family of proteins facilitate the forma-
tion of unique disulfide-dependent multimeric assembly
units. RELMb is predominantly expressed by goblet cells
and epithelial cells in the colon and is involved in the
maintenance of colonic epithelial barrier function by
upregulating MUC2 [64]. The expression of MUC2 was
increased with GOS, while RELMb and TFF3 showed
non-significant increases (Fig. 4a(ii)).
Increased levels of circulating cytokines (plasma and
serum) associated with aging have been reported in
humans and mice [28, 65, 66]. In our study, the most
important factor in modulating levels of serum cytokines
was antibiotic administration (2 × 2 × 2 ANOVA P <
0.05). Overall, the antibiotics groups had higher IL-17
and IL-6 levels in both control and GOS diets. Within
the antibiotics groups, the levels of IL-6 were higher in
the GOS diet groups, regardless of age, and higher in the
old compared to young animals in the control diet
groups (Fig. 4b(iii and iv)). Antibiotic administration
resulted in higher IP-10 and eotaxin in the control diet
groups and lower IP-10 and eotaxin in the GOS diet
groups (Fig. 4b(i and v)). Young animals had higher
levels of IL-13, regardless of diet and antibiotics (Fig. 4b(ii)).
Finally, although the levels of serum tumor necrosis factor
(TNF)α did not show significant differences between the
groups (not shown), RTqPCR analysis revealed significantly
increased gene expression of TNFα in distal colon tissue of
old mice, and prebiotics decreased the expression of the
cytokine (Fig. 4b(vi)).
Colon mucosa transcriptome profiling showed significant
differences in response to GOS diet between young and
old mice
We next aimed to determine whether GOS induced simi-
lar changes in colon gene expression in young compared
to old animals. Covariate analysis of transcriptomics data
from colon tissue of 6- versus 60-week-old mice fed the
control or GOS diets showed clear patterns of gene ex-
pression in pairwise group comparisons (Fig. 5, Supple-
mentary Table 1). Old animals fed GOS had an increased
representation of genes involved in the production of mo-
lecular mediators of the immune response (GO:0002440)
compared to old animals fed the control diet. Functions
included immunoglobulin production, positive regulation
of T-helper 1 cell cytokine production, and positive regula-
tion of immunoglobulin biosynthetic processes. Conversely,
old animals fed GOS had a lower expression of genes in the
collagen-containing extracellular matrix (GO:0062023),
specifically a disintegrin-like and metallopeptidase (reproly-
sin type) with thrombospondin type 1 motif, collagen, type
VI, alpha 1, fibronectin 1, and insulin-like growth factor
binding protein 6 (Fig. 5a).
The majority of genes (92 genes) overexpressed in young
compared to old animals fed the prebiotics diet were func-
tionally associated with binding (GO:0005488), specifically
protein binding (GO:0005515, 64 genes), ion binding (GO:
0043167, 53 genes), and protein-containing complex
binding (GO:0044877, 20 genes) (Fig. 5b). In old animals
fed GOS, genes involved in small molecule metabolic pro-
cesses (GO:0044281) and specifically the respirasome (GO:
0070469) were overexpressed compared to young animals
on the same diet (Fig. 5). In young mice, GOS also stimu-
lated the expression of the galectin gene Lgals1, which en-
codes a β-galactosyl-binding lectin that bridges molecules
by their sugar moieties, forming a signaling and adhesion
network [69]. Galectins bind specifically to β-galactoside
sugars and have been linked to host-microbe interactions
by direct binding to microorganisms affecting their survival
or function and modulating the innate or adaptive
responses of immune cells against microbes either via
extra- or intracellular mode of action. In fact, galectins can
have direct antimicrobial effects [70]. Accordingly, further
analysis of gene expression differences by mapping onto
the Kyoto Encyclopedia of Genes and Genomes (KEGG)
metabolic maps (www.genome.jp/kegg/) showed higher
expression levels of genes in focal adhesion, PI3K-Akt, and
ECM-receptor interaction pathways [71] in young
compared to old animals. The lowest expressed gene in
both old and young animals fed GOS was Trpv6 (transient
receptor potential cation channel, subfamily V, member 6),
a highly selective calcium channel that acts via calcium
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Fig. 4 (See legend on next page.)
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absorption in the intestine and kidney [72]. This gene was
overexpressed in young compared to old animals both on
the GOS and control diets.
Responders versus non-responders to GOS diets
It has been previously reported that, when fed GOS, a pro-
portion of individuals will not mount a bifidogenic re-
sponse [41, 45, 47], i.e., they will not display an
appreciable increase in the relative abundance of bifido-
bacteria. In this study, we injected stools from responder
and non-responder mice into colon organoids derived
from a single young C57BL/6J animal to determine if, by
using organoids derived from primary tissue from a single
animal colonized with stools from multiple mice and
treatments, we were capable of reproducing the bifido-
genic response-no response effect observed in vivo. Stools
from individual mice were processed, mixed with either
GOS or PBS (control), and injected into organoids derived
from the colon as previously described [73]. Organoids
were collected immediately following injection, and at 24
and 72 h after injection for 16S rRNA amplicon
sequencing and quantitative PCR analysis. Both, sequen-
cing (Fig. 6a) and qPCR data (Fig. 6b) showed that the re-
sponse (continuous lines in the figure) and non-response
(represented as dashed lines) phenotypes were reproduced
in the organoids injected with stools from both old and
young mice, albeit the response was less pronounced in
organoids injected with stools from old animals compared
to young. Shannon diversity index and species richness
values showed a rapid reduction soon after injection (Fig.
6c), with no statistically significant differences between
treatments (GOS or PBS) or between young and old sam-
ples at any time (except at baseline) in contrast with the
GOS diversity decrease observed in vivo. Principal coord-
inate analysis (PCoA) of samples showed compositional
significant differences between the groups by age (PERM
ANOVA P value = 0.01) and time (P = 0.02), while the
overall differences in microbiome composition between
PBS and GOS-treated organoids approached significance
(P = 0.06, not shown) (Fig. 6d).
At the compositional level, we observed clear differ-
ences between the original stool samples processed for
(See figure on previous page.)
Fig. 4 a (i) Old mice had higher intestinal permeability measured by FITC-dextran assays than young animals. (ii) Old mice fed GOS had
significantly increased MUC2 expression (*p < 0.05). The expression of TFF3 and RELMb tended to increase in the GOS groups, but differences
were not statistically significant. (iii) Paraformaldehyde vapor fixation and subsequent PAS staining showed increased mucus thickness in old mice
fed the prebiotics diet. b Inflammatory biomarkers were modulated by antibiotics and GOS. A 2 × 2 × 2 ANOVA test showed (i) increased serum
IP-10 in GOS-fed animals without antibiotic treatment and in antibiotic-treated animals fed control diet. (ii) Serum IL-13 levels were higher in
young animals than in old animals in all groups. (iii) IL-17 levels were higher in antibiotic-treated animals than in animals without antibiotics. (iv)
IL-6 was increased in antibiotic-treated old animals (GOS and control) compared to old animals without antibiotic treatments and elevated in
young animals treated with both GOS and antibiotics. (v) Eotaxin levels were higher in GOS-fed animals without antibiotic treatment, but lower in
GOS-fed animals that received antibiotics, regardless of age. (vi) Expression of TNFα quantified by RT-qPCR was higher in old animals compared
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Fig. 5 STRING network analysis [67] of expression data from colon showed different GOS effects on the intestinal epithelium of old and young mice. a
GOS induced expression of binding-related genes (GO:0005488) in young mice while inducing b small-molecule metabolic processes genes
(GO:0044281) in old animals. Network nodes represent predicted proteins. Splice isoforms or post-translational modifications are collapsed so each
node represents all the proteins produced by a single, protein-coding gene locus. The confidence cutoff for showing interaction links was 0.900
(highest). The lower panel in a shows the most represented GO categories within binding-related genes in our transcriptomics data. c A heatmap of
expression data revealed that GOS act as a modulator of the immune system in old and young mice. The heatmap was generated using ClustVis [68].
Rows were centered; unit variance scaling was applied to rows. Rows were clustered using correlation distance and average linkage
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injection, the microbiome of organoids injected with
young versus old samples, and between the different
treatments (GOS and PBS) (Supplementary Figures 3
and 4, and Supplementary Text). Our analysis allowed
us to identify bacterial groups especially sensitive to
manipulation, which were eliminated from the stool
sample upon processing for injection into the organoids,
potentially creating the niche for expansion of groups
originally in very low numbers.
Discussion
Our study confirmed previous reports indicating increased
intestinal permeability (a “leaky gut”) during aging [19,
28]. Consistent with previously reported data [17], old














Fig. 6 The variable bifidogenic effect observed in vivo was reproduced in vitro in the organoid platform as shown by a 16S rRNA amplicon
sequencing and b high-throughput qPCR. c Shannon diversity and species richness within microbiota-colonized organoids declined over time. d
Unweighted UniFrac PCoA plots revealed differences between old and young microbiota upon colonization in organoids, which converged to a
single grouping over 72 h. e Taxonomy plots of microbiota-colonized organoids showed changes over time in communities derived from both
old and young animals
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mice had a distinct microbiome, increased ratios of non-
saccharolytic versus saccharolytic bacteria, and corres-
pondingly, lower abundance of β-galactosidases (EC:
3.2.1.23), phospho-β-galactosidases (EC:3.2.1.85), and ara-
binogalactan endo-1,4- β-galactosidases (EC: 3.2.1.89).
Based on numerous studies detailing the beneficial effects
of prebiotic GOS, which include modulation of the gut
microbiome with specific increases in beneficial bacteria
[45, 47], stimulation of tight junctions and enhancement
of the intestinal barrier function through modulation of
goblet cells [38], reduction of inflammatory markers
release in cell culture models [39], support of intestinal
development and mucosal immune responses [40], and
reduction in adherence of enteropathogenic Escherichia
coli to tissue culture cells [74], we designed a short-term
feeding trial to determine the effects of GOS on the aging
gut microbiome and gut homeostasis. Our study also
aimed to assess the transient effects of GOS on gut
responses to antibiotic administration.
In contrast with a previous report [17], old animals
had a significantly higher abundance of Akkermansia. A.
muciniphila has been shown to reduce inflammation
[75] and improve intestinal barrier integrity [76] suggest-
ing that controlled mucolytic activity could benefit host
physiology. However, uncontrolled degradation of mu-
cins by proteolytic bacteria can increase inflammation,
damage the barrier integrity, and increase susceptibility
to pathogen infection [28, 77]. Old mice had a lower
representation of Bacteroides. Although highly variable,
the abundance of Bacteroides in aging human individuals
is also lower than in the adult population [78]. GOS had
a clear impact on the composition of the gut microbiome,
increasing mostly the abundance of non-saccharolytic bac-
teria (A. muciniphila) but also saccharolytic species (genus
Bacteroides, unknown species of the order Bacteroidales,
and species of Lactobacillus). It has been previously
reported that dietary GOS increased the abundance of
bifidobacteria in human adults [41, 47] and older adults
[55]. We also showed that GOS induced a variable bifido-
genic response in 8–12-week-old mice [45]. In this study,
we did not observe a consistent significant increase in the
abundance of bifidobacteria in old or young animals fed
the GOS diet. However, old mice did have a reduced pro-
portion of bacterial β-galactosidases (EC:3.2.1.23), suggest-
ing a reduction in metabolic potential of the microbiota.
When fed GOS diet, both old and young animals showed
an increased abundance of β-galactosidases. Reduced
abundance of intestinal saccharolytic enzymes in the aging
gut has been reported (although data is not conclusive)
[79, 80] and may have important nutritional implications
for the digestion of dietary carbohydrates by elderly
individuals.
Administration of the GOS diet reduced bacterial
diversity significantly in young and old mice. This is in
accordance with the studies of GOS-supplemented in-
fant formula [81] and in contrast with previous studies
on human adults [47, 82] and young or adult BALB/c
mice that showed no effect of GOS on bacterial diversity
[83, 84]. Alpha diversity further decreased in young ani-
mals after administration of the antibiotic cocktail in the
drinking water and remained stable throughout the
remaining course of the study. The antibiotic treatment
was selected based on the regime used in the murine
model of C. difficile infection developed by Chen et al.
[85] and includes an initial antibiotic cocktail in the
drinking water that contains kanamycin, gentamicin,
colistin, metronidazole, and vancomycin at a sufficient
dose to disrupt the microbiome and increase the suscep-
tibility to infection without major side effects. Reikvam
et al. [86] reported that mice refrained from drinking
metronidazole in water and lost weight under such treat-
ment, possibly due to the concomitant reduction in food
intake; however, in our study, animals did not lose
weight during the antibiotic treatments. Likewise, none
of the animals exhibited any signs of gastrointestinal dis-
tress or reduced activity before the clindamycin IP injec-
tion with temporary runny stools after the administration
of the second antibiotic.
Clindamycin, depending on the organism, infection
site, and concentration, can act as a bacteriostatic or
bactericidal antibiotic. This antibiotic prevents the for-
mation of peptide bonds effectively inhibiting protein
synthesis by binding to the 50S ribosomal subunit. Clin-
damycin palmitate is hydrolyzed in the gastrointestinal
tract and then distributed across the body [87]. This
antibiotic has been associated with a high incidence of
antibiotic-associated diarrhea [88]. In our study, the
antibiotic caused an expected decreased abundance of
Bifidobacterium in young and old mice on both diets.
This is in agreement with a previous in vitro report that
showed that, in contrast with the antibiotics tetracycline
and ciprofloxacin, GOS feeding after clindamycin
administration did not result in increased abundance
or recovery of bifidobacteria populations [89].
Transcriptomics analysis of the colon at the end of the
experiment indicated that GOS impacted intestinal
expression differently in young compared to old mice.
This differential modulation of host gene expression
likely plays a critical role in the differences observed in
host physiology, as well as in differential modulation of
the microbiota composition. Old animals fed the GOS
diet had increased expression of genes involved in small
molecule metabolic processes (GO:0044281) and specif-
ically the respirasome (GO:0070469). Although the role
of these respiratory enzymes organized into supercom-
plexes in the intestine has not been defined, it could be
hypothesized that they would reduce oxidative damage
increasing metabolism efficiency [90, 91].
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The effect of GOS on colonic gene expression of
young mice showed a significant enrichment in binding-
related genes (GO:0005488). Our study reports for the
first time the specific in vivo induction of the galectin
gene Lgals1, a β-galactosyl-binding lectin that bridge
molecules by their sugar moieties, forming a signaling
and adhesion network [69] by GOS diet. Previous studies
showed that dietary supplementation with a mixture of
short-chain GOS and long-chain fructo-oligosaccharides
(lcFOS) in a 9:1 ratio could be involved in the matur-
ation of the immune response in infants and induction
of oral tolerance, hence reducing the risk of developing
an allergic disease [92]. Likewise, this prebiotic mix sup-
pressed the development of acute allergic symptoms,
possibly by inducing regulatory T cells [93, 94]. The
exact mechanisms of these effects are not known; how-
ever, a study suggested that prebiotics could modulate
the immune response through galectins [95]. Intestinal
epithelial cells are crucial in maintaining homeostasis
and directing mucosal immune responses. They express
Toll-like and Nod-like receptors that recognize antigens
present in the intestinal lumen. When the Toll-like re-
ceptors are activated, intestinal epithelial cells contribute
to the modulation of immune responses by secreting
soluble mediators that bridge luminal signals with the
immunological tissues. Both antigen-presenting cells and
intestinal epithelial cells express proteins involved in the
recognition of carbohydrate (glycan) structures present
on bacterial and dietary components or glycosylated
membrane proteins expressed by other cell types.
Galectin-1 in particular have anti-inflammatory proper-
ties by enhancing the expansion and IL-10 production of
regulatory T cells, resulting in the suppression of pro-
inflammatory cytokines, including IFN-γ and TNF-α by
effector T cells [96, 97]. Further analysis showed higher
expression levels of genes in focal adhesion, PI3K-Akt,
and ECM-receptor interaction pathways [71]. Cell-
matrix adhesions play essential roles in cell motility, cell
proliferation, cell differentiation, regulation of gene
expression, and cell survival. At the cell-extracellular
matrix contact points, specialized structures (focal adhe-
sions), collections of actin filaments anchored to trans-
membrane receptors of the integrin family through a
multi-molecular complex of junctional plaque proteins,
act as structural links between membrane receptors and
the actin cytoskeleton, or as signaling molecules, includ-
ing different protein kinases and phosphatases, their
substrates, and various adapter proteins [98, 99].
Microbiome research using colonic organoids as an
in vitro platform is at its infancy [54, 100]. In this study,
we took advantage of this platform to determine if the
bifidogenic responder-non-responder phenotype [41, 45,
47] could be replicated in vitro. Injections of stools
showed that the responder and non-responder
phenotypes were reproduced in the organoids injected
with stools from old and young mice. This allowed us to
speculate that the primary contributor to the phenotype
is the presence or absence of specific taxa and specific
genetic components of the microbiota. Stool-injected
organoids showed a rapid decrease in bacterial diversity
after injection and showed compositional significant dif-
ferences between the groups by age of the donor animal,
time post-injection, and GOS treatment. This rapid de-
cline in microbial diversity post-injection is likely due in
part to oxygen exposure and limited nutrients; however,
it may also be a consequence of the absence of host fac-
tors that facilitate microbial growth and colonization. In
our study, the principal contributor to changes in the
composition of the injected organoids was time. How-
ever, the differences in the microbiome associated with
age were maintained over time, and minor differences
attributable to the prebiotics were observed. This sug-
gests that it could be possible to modify the experimen-
tal design to detect biologically relevant microbiome
differences induced by treatment. The analysis of micro-
biome composition over time allowed us to identify bac-
terial groups especially sensitive to manipulation that
were radically eliminated from the stool sample upon
processing for injection into the organoids, creating a
niche for expansion of groups originally in very low
numbers in the stool samples. It could be argued that
the differences in abundances of those bacterial groups
help to explain the differences in the GOS bifidogenic
response in vivo; however, the perturbation associated
with the preparation of stool samples for injection into
organoids was substantial causing the sharp decline in
bacteria sensitive to such manipulations. Intestinal
communities are unlikely to experience such disruptions
naturally, and hence, it seems unlikely that the bacteria
reduced by manipulation for organoid injection play a
role in bifidogenic response in vivo.
The most remarkable effect of prebiotics in the old an-
imals was the reduction of intestinal permeability and
increased mucus biosynthesis. Defects in the intestinal
barrier associated with aging have been previously re-
ported [101, 102]. A relevant study by Thevaranjan et al.
[28] reported that intestinal permeability increased with
age due to age-associated microbial dysbiosis. In their
study, increased permeability led to increased systemic
inflammation with high levels of serum IL-6. In our
study, we observed statistically non-significant increased
IL-6 levels in the old control mice that were given anti-
biotics, but not in the non-antibiotics group. IL-6 were
further increased in both young and old animals in the
antibiotics-GOS groups. Increased serum IL-6 has been
reported in neonate mice upon administration of antibi-
otics [103]. Although more studies are needed, we could
speculate that the effect of GOS potentiated the impact
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of antibiotics, in both cases through modulation of the
gut microbiome.
Conclusions
Our study showed that dietary GOS modulated homeosta-
sis of the aging gut by promoting changes in the micro-
biome composition and host gene expression, which was
translated into decreased intestinal permeability and in-
creased mucus production. It is not clear from this study if
such modulation occurred by direct GOS-host interactions
or exclusively via modulation of the microbiome. This
study also demonstrated that age is a deciding factor on
how prebiotics impact the microbiome and expression of
intestinal epithelial cells. This was especially evident from
the induction of the galectin-1 gene in young but not old
mice, which has incredible implications on the modulation
of the immune response. The present study did not
attempt to correlate the transcriptome to differences in the
microbiome; however, future studies will elucidate the
complex interactions occurring during modulation of the
host-microbes ecosystem by prebiotics.
Methods
Animal housing, treatment, and sample collection
Forty-eight female C57BL/6J SPF mice (24 6-week-old
and 24 60-week-old) received a control diet (D17121301;
Research Diets INC.) for a 2-week co-housed (6/cage)
normalization period. Animals were subsequently paired
off (1 old/1 young) from different normalization cages
and separated into groups fed control or GOS diets,
using an optimized GOS diet (D17121302; Research Di-
ets INC.) replacing 71.8 g of cellulose with 71.8 g of pure
GOS per kilogram. Pure prebiotics were generated by
heterologous expression of the beta-hexosyl transferase
from Sporobolomyces singularis in Pichia pastoris as
previously described [45, 49]. After 2 weeks, half of the
animals in each group (6 young and 6 old from each
diet) were administered an antibiotic cocktail in their
drinking water for 3 days according to the C. difficile
infection protocol described by Chen et al. [85]. The
cocktail contained kanamycin (40 mg/kg), gentamycin
(3.5 mg/kg), colistin (4.2 mg/kg), metronidazole (21.5
mg/kg), and vancomycin (4.5 mg/kg). The concentra-
tions of antibiotics in water were calculated based on the
average weight and expected water consumption of
mice. After 3 days, the water was replaced with
antibiotic-free water, and the animals were allowed 2
days to recover prior to receiving an intraperitoneal in-
jection of clindamycin (10 μg/g body weight). Animals
remained on their respective diets and were sacrificed
following a 1-week recovery period. For both experi-
ments, fresh stool samples were collected and stored at
− 80 °C. Intestinal tissues and contents were collected at
termination (Fig. 2a). Animal weight and behavior were
monitored throughout the study.
Mouse intestinal permeability assay
Mice were administered 100 mg fluorescein isothiocyan-
ate (FITC) dextran/100 g body weight via oral gavage 4 h
prior to sacrifice. Immediately following euthanasia,
blood was harvested via cardiac puncture, and the serum
was subsequently separated via centrifugation. The
serum from each animal was assayed for the presence
and quantity of FITC signal with a TECAN Infinite
M200 plate reader, using an excitation wavelength of
485 nm and an emission wavelength of 528 nm. A stand-
ard curve of FITC dextran was used to quantify the
signal in each serum sample.
Mucin staining and tissue imaging
The sections of mouse distal colon were harvested,
embedded in optimal cutting temperature (OCT)
compounding agent, and flash-frozen in a dry ice-filled
ethanol bath without fixation. Blocks were stored at − 80
°C until cut at − 20 °C on a cryostat, and frozen sections
were mounted onto slides. The sections were immedi-
ately subject to paraformaldehyde vapor fixation (4%
PFA, 60C) for 8 h prior to PAS staining and subsequent
imaging on Nikon 2000-E inverted widefield microscope.
Images were saved as RFG files and uploaded to the
ImageJ Analysis software, where pixel analysis was
performed to quantify the abundance of mucin/mucin-
producing cells (blue/purple) and epithelial cells (pink).
Organoid cultivation and colonization
Organoids were derived from colon crypts harvested from
a single young C57BL/6J and grown in 96-well plates em-
bedded in Corning® Matrigel® matrix (Corning Inc., Corn-
ing NY) and overlaid with complex DMEM-F12 growth
media containing 1 μg/ml Pen Strep [104, 105]. Organoids
were incubated at 37 °C under 5% CO2 and ambient oxy-
gen and were passaged into new plates every 10–14 days.
Organoids used for injection were grown 4 days post-
passage and were uniform in size and shape. Homoge-
nized stool samples collected from both young and old
donor mice prior to GOS treatment were filtered through
5-μM syringe filters (Millipore) and loaded into micro-
injection needles for organoid inoculation as previously
described [54]. Loaded needles were attached to the injec-
tion apparatus, and organoids were injected with ~ 400 pL
of stool suspension. Injected organoids were then incu-
bated at 37 °C under 5% CO2 and ambient oxygen with
supplemental antibiotics. Organoids were harvested at 0 h,
24 h, and 72 h post-injection.
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Nucleic acid isolation
DNA from fecal samples and microbiota-colonized orga-
noids were extracted using the Qiagen DNeasy stool
DNA isolation kit (Qiagen, Valencia, CA) with an
additional bead-beating step aimed to ensure uniform
lysis of bacterial spores. Samples were loaded into tubes
containing 10mg of sterile, acid washed, 1 μm glass
beads, and homogenized for 5 min at 15 Hz in Qiagen
TissueLyser II (Qiagen, Valencia, CA). DNA was subse-
quently used for 16S rRNA amplicon sequencing and
whole-genome shotgun sequencing. RNA isolation from
tissues was performed using the Qiagen RNeasy kit (Qiagen,
Valencia, CA) following the manufacturer’s instructions for
subsequent use in RTqPCR and mRNA sequencing.
High-throughput quantitative PCR detection of
Bifidobacterium
The Access array AA 24.192 (Fluidigm Corporation, San
Francisco, CA) was used in the UNC Advanced Analyt-
ics Core. Primers for amplification of the 16S rRNA
gene and GroEL have been validated in previous studies
[106–109]. The taxonomic groups targeted in the Bifido-
bacterium array include domain Bacteria, phylum Acti-
nobacteria, genus Bifidobacterium, and Bifidobacterium
species. Pre-amplification (specific target amplification
(STA)) assays and microfluidic qPCR were be performed
on a BioMark HD reader as described [45]. Raw data
were normalized using the Livak method [110]. Cq
values for each sample were normalized against their re-
spective Cq value obtained from universal primers using
the equation: ratio (reference/target) = 2−Ct (ref)-Ct (target).
16S rRNA amplicon sequencing
Total DNA was subject to amplification of the V4 region
of the 16S rRNA gene using primers (515F-806R) with
Illumina adaptors. Amplicons were barcoded using
Illumina dual-index barcodes (Index 1(i7) and Index
2(i5)), purified using Agencourt® AMPure® XP Reagent
(Beckman Coulter, Brea, CA) and quantified with Quant-
iT™ PicoGreen® dsDNA Reagent (Molecular Probes,
Thermo Fisher Scientific, Waltham, MA). Libraries were
pooled in equimolar amounts and sequenced on MiSeq
(Illumina, San Diego, CA).
Data analysis
Sequencing output from the Illumina MiSeq platform
was converted to fastq format and demultiplexed using
Illumina Bcl2Fastq 2.18.0.12. The resulting paired-end
reads were processed using QIIME 2 [111] 2018.11.
Index and linker primer sequences were trimmed using
the QIIME 2 invocation of cutadapt. The resulting paired-
end reads were processed with DADA2 through QIIME 2
including merging paired ends, quality filtering, error
correction, and chimera detection. An average of 81,904
filtered, denoised, merged, non-chimeric sequences wase
produced per sample. Amplicon sequencing units from
DADA2 were assigned taxonomic identifiers using Green
Genes release 13_08. Alpha diversity indexes (Faith PD
whole tree, EVENNESS (Shannon), and observed species)
were estimated using QIIME 2 at a rarefaction depth of
10,000 sequences per sample. Beta diversity estimates
were calculated within QIIME 2 using weighted and un-
weighted UniFrac distances as well as Bray-Curtis dissimi-
larity between samples at an initial subsampling depth of
5000 and then 1000 since antibiotic-treated samples had
lower yields than non-antibiotic samples. The results were
summarized and visualized through principal coordinate
analysis, and significance was estimated as implemented
in QIIME 2. Significance of differential abundance was
estimated using ANCOM as implemented in QIIME 2.
Assignment of saccharolytic (SAC) and non-saccharolytic
(NON_SAC) to bacterial taxa
We used the reference study by Vieira-Silva et al. [112],
which mined 532 publicly available gut reference ge-
nomes and assigned them to four different groups (pro-
teolytic, saccharolytic, lipolytic, and generalist bacteria)
using metagenome analytical methods, and the study by
Magnusdottir et al. [113] on the metabolic reconstruc-
tion network AGORA. In the case that the genus was
not categorized in the mentioned studies, we referred to
the Bergey’s Manual of Systematic Bacteriology [114] and
previously published reports when the genus was not
found in either source [115–126]. We included sacchar-
olytic and generalist bacteria in the SAC group, as well
as chemolithoheterotrophic bacteria capable of using
either carbohydrates or the metabolites derived from
carbohydrate sources (for example, Dehalobacter, Geo-
bacillus). Likewise, the NON_SAC category included
proteolytic and lipolytic bacteria.
Whole-Genome Shotgun (WGS) sequencing
One nanogram of intact genomic DNA was processed
using the Nextera XT DNA Sample Preparation Kit
(Illumina, San Diego, CA). In this process, the target
DNA was simultaneously fragmented and tagged by the
Nextera Enzyme Mix containing transposome, which
fragments the input DNA and adds bridge PCR (bPCR)-
compatible adaptors required for binding and clustering
on the flow cell. Next, fragmented DNA was amplified
via a limited-cycle PCR program adding index 1(i7) and
index 2(i5) (Illumina) in a unique combination for each
sample, as well as primer sequences required for cluster
formation. Libraries were purified using Agencourt®
AMPure® XP Reagent (Beckman Coulter, Brea, CA) and
quantified with Quant-iT™ PicoGreen® dsDNA Reagent
(Molecular Probes, Thermo Fisher Scientific, Waltham,
MA). All libraries were pooled in equimolar amounts and
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heat-denatured before loading on Illumina HiSeq2000
Rapid.
Data analysis
Sequencing output from the Illumina platform was con-
verted to fastq format and demultiplexed using Illumina
Bcl2Fastq 2.18.0.12. An average of 11 million reads was
generated per sample. Quality control of the demulti-
plexed sequencing reads was verified by FastQC. The
resulting paired-end reads were aligned with Bowtie2
[127] against the host reference, and all aligning reads will
be eliminated. Paired-end reads were joined with vsearch
1.10.2. The resulting single-end reads were again aligned
against the reference with Bowtie2 retaining all reads that
did not align. Estimates of taxonomic composition, gene
family, path abundance, and path coverage were produced
from the remaining reads using HUMAnN2 [128].
Reverse transcription qPCR
1.5 μg of total RNA was subject to reverse transcription
using the iScript Advanced cDNA synthesis kit (Bio-Rad,
Hercules, CA). Total nucleic acid was subsequently
quantified and normalized to 1 ng/μl prior to qPCR
setup. qPCR reactions were performed using the Power-
SYBR Green Master Mix, 3 ng of total nucleic acid per
reaction, and the following primer pairs (at a final con-
centration of 100 nM): TNFa (Fwd: 5′-ACGGCATGGA
TCTCAAAGAC-3′, Rev: 5′-GTGGGTGAGGAGCACG
TAGT-3′) [129], IL-6 (Fwd: 5′-CTGCAAGAGACTTC
CATCCAGTT-3′, Rev: 5′-GAAGTAGGGAAGGCCG
TGG-3′) [130], GapDH (Fwd: 5′-TGCACCACCACCAA
CTGCTTAG-3′, Rev: 5′-GGATGCAGGGATGATGTT
C-3′) [131], Muc2 (Fwd: 5′-GCTGACGAGTGGTTGG
TGAATG-3′, Rev: 5′-GATGAGGTGGCAGACAGG
AGAC-3′) [132], RELMβ (Fwd: 5′-CCATTTCCTG
AGCTTTCTGG-3′, Rev: 5′-AGCACATCCAGTGACA
ACCA-3′) [133], and TFF3 (Fwd: 5′-CAGATTACGT
TGGCCTGTCTCC-3′, Rev: 5′-ATGCTTGCTACCCT
TGGACCAC-3′) [133]. qPCR reactions were performed
on the QuantStudio Q6 instrument (Thermo Fisher
Scientific, Waltham, MA). The samples were run in
technical triplicate, and included no template, and no
reverse transcriptase controls in addition to the internal
GapDH control for normalization of gene expression.
Cycle threshold values (CT) were calculated from ampli-
fication plot data by the QuantStudio6 software at the
completion of each qPCR run. CT values were normal-
ized to the internal GapDH controls to generate ΔCT
values for each gene in each animal. ΔΔCT values were
generated by comparing the ΔCT values from control ani-
mals within an age group to the ΔCT values from experi-
mental animals within that same group. Fold change (FC)
of gene expression of each target gene between groups
was calculated by using the following equation: FC =
2^(−ΔΔCT).
Mouse mRNA sequencing
Total RNA isolated from mouse colon was processed
using the NuGEN Universal Plus mRNA-Seq kit (NuGEN
Technologies, Inc., San Carlos, CA) for whole transcrip-
tome sequencing as directed by the manufacturer. Briefly,
total RNA was subject to poly(A) selection, fragmentation,
first-strand synthesis, second-strand synthesis, end repair,
adaptor ligation, strand selection, and finally library ampli-
fication. Indexed cDNA libraries quantified via Quant-iT™
PicoGreen® dsDNA reagent (Thermo Fisher Scientific,
Waltham, MA) were pooled at equimolar concentrations
and sequenced on Illumina HiSeq4000 platform.
Data analysis
Demultiplexed paired-end reads from mRNA sequencing
experiments were aligned with STAR [134] against the
mouse Mm9 reference. Salmon [135] was applied to the
resulting alignment to estimate the quantity of transcript
expression. The significance of differential expression
was measured with DESeq2 [136].
Cytokine analysis
Serum was subject to Milliplex cytokine/chemokine
assay MCYTOMAG-70K (Millipore, Sigma, Burlington,
MA) for the detection and quantification of TNFα, IP-
10, IL-17, IL-13, IL-10, IL-6, IL-4, IL-1α, eotaxin, IL-12,
and IL-7. The assay was run at the UNC Advanced Analytics
Core on DropArray™96 Plate system (Curiox Biosystems,
San Carlos, CA) as recommended by the manufacturer.
Statistical analyses
Group differences were tested for statistical significance
using ANOVA with ad hoc Tukey tests for pairwise
comparisons, and P values were reported accordingly.
Differences in the microbiota composition were deter-
mined using non-parametric tests (Kruskal-Wallis or
Mann-Whitney as appropriate) and analysis of compos-
ition of microbiomes (ANCOM) [137] analyses. FDR
correction was applied to the statistical analysis of samples
to take into consideration multiple comparisons. Differ-
ences in beta diversity were determined using analysis of
similarity (ANOSIM) and permutational multivariate
analysis of variance (PERMANOVA) analyses in QIIME2.
Statistical differences in the relative abundance of beta-
galactosidases were determined using the Kruskal-Wallis H
test with FDR correction in STAMP [138]. Unless other-
wise indicated, the cutoff for statistical significance was set
to P < 0.05 for the determination of differences between
the groups in the microbiota, gene expression, intestinal
permeability, and cytokine analyses.
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Additional file 1: Figure S1. Relative abundance of Bacteroides (a),
Akkermansia muciniphila (b), and Lactobacillus (c) were increased by GOS
diets. Abundance of Clostridium (d), Adlecreutzia (e) and Ruminococcus (f)
were reduced by GOS diets.
Additional file 2: Figure S2. Individual pixel-pigment analysis of mucus
staining of tissue samples revealed a distinctly higher abundance of pixels
in the lower range of the pigment spectrum (darker colors, blue and pur-
ple) in GOS-fed old animals, compared to young or control-fed old ani-
mals (a). Pigment-specific histograms of the RGB image files were
generated using ImageJ software, revealing differences between samples
in the abundance of pixels in each image, as well as providing quantifica-
tion of pixels within each pigment range (b). Ratios between epithelial
and mucosal pixels were calculated and used in determining the fold
change in pigment between specific pairs of animals, Old animals GOS vs
Control diets, Young animals GOS vs Control diets, Old animals vs Young
animals feeding on control diet, and finally Old animals vs Young animals
feeding on GOS diet (c). Mucus fold change was calculated for each ani-
mal compared to Young animals fed control diet (d).
Additional file 3: Figure S3. Heatmap represents changes in bacterial
abundance within old microbiota-colonized organoids over time when
supplemented with either PBS (control), GOS, or Lactose.
Additional file 4: Figure S4. Heatmap represents changes in bacterial
abundance within young microbiota-colonized organoids over time
when supplemented with either PBS (control), GOS, or Lactose.
Additional file 5. Supplementary text.
Additional file 6: Table S1. Diet composition as provided by the
manufacturers.
Additional file 7: Table S2. Expression data from colons of young and
old mice fed either the control or GOS diets.
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